A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-response Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus
Phase of Trial: Phase II
Latest Information Update: 22 May 2017
At a glance
- Drugs Cenerimod (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Actelion Pharmaceuticals
- 22 May 2017 Results published in an Actelion Pharmaceuticals media release.
- 13 Mar 2017 Status changed from active, no longer recruiting to completed.
- 10 Nov 2016 Status changed from recruiting to active, no longer recruiting.